Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Buy” by Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received an average recommendation of “Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $19.00.

AMRX has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Barclays upped their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $22.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. Finally, UBS Group upped their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $17.47 on Tuesday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a 50 day moving average price of $17.71 and a 200 day moving average price of $14.88. The stock has a market capitalization of $5.58 billion, a PE ratio of 35.65 and a beta of 1.27. Amneal Pharmaceuticals has a 52 week low of $9.32 and a 52 week high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Analysts predict that Amneal Pharmaceuticals will post 0.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares of the company’s stock, valued at $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares in the company, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several large investors have recently modified their holdings of AMRX. Kemnay Advisory Services Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth about $26,000. Public Employees Retirement System of Ohio acquired a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $29,000. Federated Hermes Inc. grew its position in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after purchasing an additional 2,168 shares during the last quarter. Comerica Bank grew its position in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the last quarter. Finally, Transamerica Financial Advisors LLC increased its stake in shares of Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.